Ron Stotish, CEO of AquaBounty Technologies, believes genetically modified salmon is no threat to its opponents and the outlook for AquAdvantage is good. With its purchase of the Bell Fish Co. RAS facility, commercialization will soon commence.
Ron Stotish, CEO of AquaBounty Technologies, discusses being the first to produce a genetically modified (GM) farmed salmon deemed safe for consumption, the controversy surrounding his company's product and the potential of biotechnology.
An article by FactCheck.org concluded that fears regarding risk to human and environmental health posed by GM salmon are unfounded. Meanwhile, a group of environmental NGOs has sued the U.S. Food and Drug Administration over its approval of the fish
Scott Nichols speaks to the Advocate about the launch of his own consultancy, Food’s Future, about groundbreaking innovations at Verlasso and about the role of aquaculture in a rapidly changing world — one in need of collaboration and new ideas.
After a 20-year process, a genetically modified fish earned U.S. Food and Drug Administration approval, reigniting one of the seafood industry’s most intriguing controversies. Here are 10 key downloads from the groundbreaking decision over AquAdvantage salmon.